NCT05318196 Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
| NCT ID | NCT05318196 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Acute Kidney Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2022-09-05 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2022-09-05 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.
Eligibility Criteria
Inclusion Criteria: * Patients (\> 18 year of age) with kidney disease or at risk to develop a kidney disease, * Patients followed by a practitioner of the Department of Nephrology and Organ Transplantations of the University Hospital of Toulouse (France) Exclusion Criteria: * consent deny * inability of the patient or its family to give consent.
Contact & Investigator
Stanislas Faguer, MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Toulouse
Frequently Asked Questions
Who can join the NCT05318196 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05318196 currently recruiting?
Yes, NCT05318196 is actively recruiting participants. Contact the research team at faguer.s@chu-toulouse.fr for enrollment information.
Where is the NCT05318196 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT05318196 clinical trial?
NCT05318196 is sponsored by University Hospital, Toulouse. The principal investigator is Stanislas Faguer, MD, PhD at University Hospital, Toulouse. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.